Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112735 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Qiaoyun Zheng und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, F…. Hauptthemen laut MEDLINE: Hemophilia A, Factor VIII, Antibodies, Monoclonal, Chemokine CXCL13. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Anti-factor VIII (FVIII) antibody development poses a significant challenge in hemophilia A (HA) patients receiving FVIII protein replacement therapy. There is an urgent need for novel therapeutic strategies to inhibit the production of anti-FVIII inhibitory antibodies (inhibitors) in HA. This study aimed to investigate a combination monoclonal antibody (mAb) therapy targeting CXCL13 and CD20 on the development of anti-FVIII antibodies in a HA murine model, along with the underlying mechanisms involved. Specifically, mAbs targeting mouse CD20 (18B12) with an IgG2a backbone and mouse CXCL13 (2C4) with an IgG1 backbone were synthesized. HA mice with FVIII inhibitors were established, and the results revealed that the combination therapy of anti-mCD20 with α-mCXCL13 significantly suppressed anti-FVIII antibody development and induced FVIII tolerance. Furthermore, this combination therapy led to a marked reduction of peripheral and splenic follicular helper T cells and an enhancement of regulatory T cell induction, along with sustained depletion of bone marrow and splenic plasma cells in HA mice with preexisting FVIII immunity. Thus, the concurrence of blockage of CD20 and neutralization of CXCL13 hold promise as a therapeutic strategy for HA patients with inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
- Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA; Blood Research Institute, Versiti, Milwaukee, WI, USA.
- Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Electronic address: wuyong9195@126.com.
- Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fu…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zheng, Q., Lin, K., Zhang, N., Shi, Q., Wu, Y., & Chen, Y. (2024). Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112735
Vancouver
Zheng Q, Lin K, Zhang N, Shi Q, Wu Y, Chen Y. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112735
BibTeX
@article{Zheng2024,
author = {Zheng, Qiaoyun and Lin, Kehan and Zhang, Na and Shi, Qizhen and Wu, Yong and Chen, Yingyu},
title = {Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112735}
}
EUVIMED